Wrinkled non-spherical microparticles as a new microcarrier for cell culture applications in Sanofi Pasteur

皱纹非球形微粒作为赛诺菲巴斯德细胞培养应用的新型微载体

• 批准号: 508822-2017
• 负责人: Hwang, DaeKun
• 金额: $ 1.82万
• 依托单位: Ryerson University
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=639916
• 关键词: Wrinkled; non; spherical; microparticles; new

Mammalian cells used to produce various vaccines in bioreactors are typically grown on a support matrixtermed a microcarrier, which can be made of a number of different materials including DEAE-dextran, glass,polystyrene plastic, acrylamide, collagen, and alginate. Commercial microcarriers are only available in smoothsurface, spherical forms. Spheres have the smallest surface-area-to-volume ratio, and therefore the least surfacespace available for cells to attach for a given volume. In addition to their spherical shape, the smooth surface ofavailable microcarriers makes it difficult to increase the surface area for cell culture capacity improvement.Another challenge in current microcarrier-based cell culture is that the microcarrier surface needs to bechemically modified prior to cell attachment and detachment (recovery) - often involving expensive enzymes.The Hwang group at Ryerson has developed a technique that can produce microcarriers with designed shapesand tuneable surface wrinkles that can significantly increase their surface area. When used for cell culture,these microcarriers can greatly improve cell attaching capacity. In addition, the microcarrier surface is notchemically modified, which simplifies the cell attaching and recovery process without using enzymes.Sanofi Pasteur is a world leading vaccine manufacturing company, and its head office in Toronto has Canada'slargest vaccine R&D facility. Sanofi manufactures several vaccines through mammalian cell culture usingmicrocarriers. This Engage grant will enable Sanofi and the Ryerson team to begin working towardssuccessfully integrating these non-spherical-microcarrier-based technologies into their vaccine production. As aresult, cell culture efficiency and vaccine production at Sanofi can be significantly improved in the future.

用于在生物反应器中生产各种疫苗的哺乳动物细胞通常生长在称为微载体的载体基质上，微载体可以由多种不同的材料制成，包括DEAE-葡聚糖、玻璃、聚苯乙烯塑料、丙烯酰胺、胶原和海藻酸盐。商用微载体只能以光滑的球形形式提供。球体具有最小的表面积与体积比，因此对于给定的体积，可供细胞附着的表面空间最小。除了球形外，现有微载体的光滑表面使得增加细胞培养能力的表面积变得困难。目前基于微载体的细胞培养的另一个挑战是在细胞附着和分离(恢复)之前需要对微载体表面进行化学修饰-通常涉及昂贵的酶。Ryerson的Hwang团队开发了一种技术，可以生产具有设计形状和可调表面皱纹的微载体，这可以显著增加其表面积。当用于细胞培养时，这些微载体可以极大地提高细胞贴壁能力。此外，微载体表面无需化学修饰，简化了细胞附着和回收过程，无需使用酶。赛诺菲巴斯德是世界领先的疫苗制造公司，其位于多伦多的总部拥有加拿大最大的疫苗研发设施。赛诺菲使用微载体通过哺乳动物细胞培养生产了几种疫苗。这笔Engage赠款将使赛诺菲和瑞尔森团队能够开始努力，成功地将这些基于非球形微载体的技术整合到他们的疫苗生产中。因此，赛诺菲的细胞培养效率和疫苗生产在未来可以显著提高。